特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エピネフリン自己注射器の世界市場:2020年~2024年

Global Epinephrine Autoinjector Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 282669
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
エピネフリン自己注射器の世界市場:2020年~2024年 Global Epinephrine Autoinjector Market 2020-2024
出版日: 2020年04月21日 ページ情報: 英文 120 Pages
概要

世界のエピネフリン自己注射器市場は、2020年から2024年にかけて7%のCAGRで推移し、市場規模は7億6,251万米ドルに達すると予測されています。アレルギーの罹患率の上昇や、技術進歩、マーケティング戦略の拡大などにより当市場の成長が促進される見通しです。

当レポートでは、世界のエピネフリン自己注射器市場を調査し、市場の概要、投与量・年齢層・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および課題、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模
  • 市場の見通し

ファイブフォース分析

市場セグメンテーション:投与量別

  • 市場区分:投与量別
  • 市場比較:投与量別
  • 0.30 gm
  • 0.15 gm
  • 0.50 gm
  • 市場機会:投与量別

市場セグメンテーション:年齢層別

  • 市場区分:年齢層別

市場セグメンテーション:エンドユーザー別

  • 市場区分:エンドユーザー別
  • 市場比較:エンドユーザー別
  • 病院・診療所
  • 個人
  • 市場機会:エンドユーザー別

顧客情勢

  • 概要

市場セグメンテーション:地域別

  • 市場区分:地域別
  • 市場比較:地域別
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会:地域別
  • 需要促進要因 - 需要主導の成長
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 創造的破壊の状況
  • 競合シナリオ

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Adamis Pharmaceuticals Corp.
  • ALK-Abello AS
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • kaleo Inc.
  • Lincoln Medical Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

付録

目次
Product Code: IRTNTR43297

Technavio has been monitoring the epinephrine autoinjector market and it is poised to grow by $ 762.51 mn during 2020-2024 progressing at a CAGR of 7% during the forecast period. Our reports on epinephrine autoinjector market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of allergies, technological advances and marketing strategies. In addition, increasing prevalence of allergies is anticipated to boost the growth of the market as well.

The epinephrine autoinjector market analysis include end-user segment and geographic landscapes

Technavio's ‘ epinephrine autoinjector market ’ is segmented as below:

By End-user:

  • Hospitals
  • Clinics
  • Individuals

By Geographic Landscapes:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the tentative product launches as one of the prime reasons driving the epinephrine autoinjector market growth during the next few years. Also, growing awareness about epinephrine autoinjectors and patient assistance programs will lead to sizable demand in the market.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our epinephrine autoinjector market covers the following areas:

  • Epinephrine autoinjector market sizing
  • Epinephrine autoinjector market forecast
  • Epinephrine autoinjector market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epinephrine autoinjector market vendors that include Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.. Also, the epinephrine autoinjector market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Force Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Dosage

  • Market segments
  • Comparison by Dosage
  • 0.30gm - Market size and forecast 2019-2024
  • 0.15gm - Market size and forecast 2019-2024
  • 0.50gm - Market size and forecast 2019-2024
  • Market opportunity by Dosage

Market Segmentation by Age Group

  • Market segmentation by Age Group

Market Segmentation by End-user

  • Hospitals and clinics
  • Individuals

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - demand-led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Adamis Pharmaceuticals Corp.
  • ALK-Abello AS
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • kaleo Inc.
  • Lincoln Medical Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: 0.30gm - Market size and forecast 2019-2024 ($ million)
  • 24: 0.30gm - Year-over-year growth 2019-2024 (%)
  • 25: 0.15gm - Market size and forecast 2019-2024 ($ million)
  • 26: 0.15gm - Year-over-year growth 2019-2024 (%)
  • 27: 0.50gm - Market size and forecast 2019-2024 ($ million)
  • 28: 0.50gm - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Adamis Pharmaceuticals Corp. - Overview
  • 50: Adamis Pharmaceuticals Corp. - Product and service
  • 51: Adamis Pharmaceuticals Corp. - Key offerings
  • 52: Adamis Pharmaceuticals Corp. - Key customers
  • 53: Adamis Pharmaceuticals Corp. - Segment focus
  • 54: ALK-Abello AS - Overview
  • 55: ALK-Abello AS - Product and service
  • 56: ALK-Abello AS - Key offerings
  • 57: ALK-Abello AS - Key customers
  • 58: ALK-Abello AS - Segment focus
  • 59: Amneal Pharmaceuticals Inc. - Overview
  • 60: Amneal Pharmaceuticals Inc. - Business segments
  • 61: Amneal Pharmaceuticals Inc. - Key offerings
  • 62: Amneal Pharmaceuticals Inc. - Key customers
  • 63: Amneal Pharmaceuticals Inc. - Segment focus
  • 64: Bausch Health Companies Inc. - Overview
  • 65: Bausch Health Companies Inc. - Business segments
  • 66: Bausch Health Companies Inc. - Key offerings
  • 67: Bausch Health Companies Inc. - Key customers
  • 68: Bausch Health Companies Inc. - Segment focus
  • 69: kaleo Inc. - Overview
  • 70: kaleo Inc. - Product and service
  • 71: kaleo Inc. - Key offerings
  • 72: kaleo Inc. - Key customers
  • 73: kaleo Inc. - Segment focus
  • 74: Lincoln Medical Ltd. - Overview
  • 75: Lincoln Medical Ltd. - Product and service
  • 76: Lincoln Medical Ltd. - Key offerings
  • 77: Lincoln Medical Ltd. - Key customers
  • 78: Lincoln Medical Ltd. - Segment focus
  • 79: Mylan NV - Overview
  • 80: Mylan NV - Business segments
  • 81: Mylan NV - Key offerings
  • 82: Mylan NV - Key customers
  • 83: Mylan NV - Segment focus
  • 84: Novartis AG - Overview
  • 85: Novartis AG - Business segments
  • 86: Novartis AG - Key offerings
  • 87: Novartis AG - Key customers
  • 88: Novartis AG - Segment focus
  • 89: Pfizer Inc. - Overview
  • 90: Pfizer Inc. - Business segments
  • 91: Pfizer Inc. - Key offerings
  • 92: Pfizer Inc. - Key customers
  • 93: Pfizer Inc. - Segment focus
  • 94: Teva Pharmaceutical Industries Ltd. - Overview
  • 95: Teva Pharmaceutical Industries Ltd. - Business segments
  • 96: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 97: Teva Pharmaceutical Industries Ltd. - Key customers
  • 98: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations